Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Purpura, Thrombocytopenic, Idiopathic | 28 | 2024 | 241 | 14.150 |
Why?
|
Telangiectasia, Hereditary Hemorrhagic | 23 | 2024 | 141 | 13.050 |
Why?
|
Thrombocytopenia | 31 | 2024 | 1174 | 11.500 |
Why?
|
Anemia, Hemolytic, Congenital Nonspherocytic | 16 | 2024 | 55 | 8.010 |
Why?
|
Pyruvate Metabolism, Inborn Errors | 15 | 2024 | 49 | 7.450 |
Why?
|
Receptors, Thrombopoietin | 21 | 2024 | 161 | 6.530 |
Why?
|
Thrombopoietin | 21 | 2024 | 226 | 6.440 |
Why?
|
Pyruvate Kinase | 17 | 2024 | 190 | 5.500 |
Why?
|
Receptors, Fc | 19 | 2024 | 534 | 4.320 |
Why?
|
Recombinant Fusion Proteins | 20 | 2024 | 3735 | 3.350 |
Why?
|
Benzoates | 11 | 2024 | 212 | 3.180 |
Why?
|
Thrombosis | 14 | 2024 | 3052 | 2.800 |
Why?
|
Hydrazines | 9 | 2024 | 224 | 2.800 |
Why?
|
Epistaxis | 11 | 2024 | 111 | 2.680 |
Why?
|
Hemorrhage | 17 | 2024 | 3600 | 2.500 |
Why?
|
Venous Thromboembolism | 14 | 2023 | 1864 | 2.500 |
Why?
|
Thiophenes | 8 | 2023 | 587 | 2.340 |
Why?
|
Anemia | 7 | 2022 | 1511 | 2.130 |
Why?
|
Anticoagulants | 17 | 2023 | 4897 | 1.830 |
Why?
|
Pyrazoles | 9 | 2024 | 1999 | 1.830 |
Why?
|
Hematologic Agents | 3 | 2018 | 41 | 1.830 |
Why?
|
Hemophilia A | 3 | 2022 | 359 | 1.800 |
Why?
|
Blood Coagulation | 5 | 2020 | 1157 | 1.580 |
Why?
|
Angiodysplasia | 2 | 2021 | 22 | 1.540 |
Why?
|
Quinolines | 6 | 2024 | 759 | 1.520 |
Why?
|
Thiazoles | 8 | 2023 | 1511 | 1.500 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 3 | 2020 | 264 | 1.480 |
Why?
|
Blood Platelet Disorders | 2 | 2021 | 61 | 1.370 |
Why?
|
Hematologic Neoplasms | 4 | 2022 | 1895 | 1.340 |
Why?
|
Antineoplastic Agents | 12 | 2024 | 13630 | 1.320 |
Why?
|
Anemia, Aplastic | 2 | 2022 | 228 | 1.320 |
Why?
|
Iron Overload | 3 | 2024 | 240 | 1.220 |
Why?
|
Platelet Count | 10 | 2024 | 777 | 1.140 |
Why?
|
Platelet Factor 4 | 2 | 2024 | 129 | 1.130 |
Why?
|
Neoplasms | 13 | 2024 | 22072 | 1.120 |
Why?
|
von Willebrand Diseases | 3 | 2024 | 132 | 1.070 |
Why?
|
Piperazines | 6 | 2024 | 2525 | 1.060 |
Why?
|
End Stage Liver Disease | 2 | 2021 | 353 | 1.040 |
Why?
|
Blood Platelets | 5 | 2024 | 2520 | 1.040 |
Why?
|
Venous Thrombosis | 4 | 2023 | 1299 | 1.000 |
Why?
|
Humans | 143 | 2024 | 760621 | 0.990 |
Why?
|
Thrombophilia | 5 | 2021 | 306 | 0.950 |
Why?
|
Hematologic Diseases | 3 | 2024 | 496 | 0.940 |
Why?
|
Liver Diseases | 4 | 2021 | 1302 | 0.940 |
Why?
|
Tranexamic Acid | 3 | 2021 | 176 | 0.830 |
Why?
|
von Willebrand Disease, Type 2 | 1 | 2021 | 7 | 0.800 |
Why?
|
Angiogenesis Inhibitors | 8 | 2024 | 2049 | 0.790 |
Why?
|
Antifibrinolytic Agents | 5 | 2024 | 292 | 0.780 |
Why?
|
Blood Coagulation Disorders | 2 | 2024 | 349 | 0.760 |
Why?
|
Hemophilia B | 1 | 2022 | 84 | 0.760 |
Why?
|
Factor VIIa | 1 | 2022 | 103 | 0.760 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2022 | 177 | 0.740 |
Why?
|
Thrombocytosis | 1 | 2021 | 82 | 0.730 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 2021 | 285 | 0.720 |
Why?
|
Anemia, Iron-Deficiency | 2 | 2024 | 368 | 0.720 |
Why?
|
Anemia, Hemolytic | 1 | 2021 | 163 | 0.720 |
Why?
|
Autoantibodies | 6 | 2024 | 2118 | 0.720 |
Why?
|
Neutropenia | 2 | 2024 | 884 | 0.710 |
Why?
|
Wiskott-Aldrich Syndrome | 1 | 2020 | 130 | 0.710 |
Why?
|
Doxycycline | 1 | 2022 | 341 | 0.700 |
Why?
|
Hexokinase | 1 | 2020 | 125 | 0.690 |
Why?
|
Antiphospholipid Syndrome | 1 | 2021 | 165 | 0.680 |
Why?
|
Cyclosporine | 1 | 2022 | 777 | 0.670 |
Why?
|
Hemoglobins | 6 | 2022 | 1521 | 0.660 |
Why?
|
Intergenerational Relations | 1 | 2019 | 68 | 0.660 |
Why?
|
Atrial Appendage | 1 | 2023 | 292 | 0.660 |
Why?
|
Porphyria, Acute Intermittent | 1 | 2019 | 15 | 0.660 |
Why?
|
Aortic Valve Stenosis | 2 | 2022 | 2065 | 0.650 |
Why?
|
Thalidomide | 1 | 2024 | 884 | 0.650 |
Why?
|
Gastrointestinal Hemorrhage | 6 | 2024 | 1131 | 0.640 |
Why?
|
Hematology | 1 | 2022 | 241 | 0.630 |
Why?
|
Liver Transplantation | 2 | 2021 | 2325 | 0.620 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2019 | 412 | 0.620 |
Why?
|
Perforin | 1 | 2018 | 167 | 0.620 |
Why?
|
Antibodies, Bispecific | 1 | 2020 | 191 | 0.600 |
Why?
|
Hemoptysis | 1 | 2019 | 152 | 0.590 |
Why?
|
Erythrocytes | 3 | 2022 | 2415 | 0.560 |
Why?
|
Standard of Care | 1 | 2021 | 552 | 0.560 |
Why?
|
Plasma | 1 | 2020 | 584 | 0.560 |
Why?
|
Adult | 40 | 2024 | 219994 | 0.550 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 130 | 0.550 |
Why?
|
Vascular Malformations | 1 | 2022 | 464 | 0.540 |
Why?
|
Bacterial Vaccines | 1 | 2018 | 401 | 0.530 |
Why?
|
Drug Hypersensitivity | 2 | 2022 | 916 | 0.530 |
Why?
|
Phenylthiohydantoin | 1 | 2017 | 204 | 0.520 |
Why?
|
Truth Disclosure | 1 | 2019 | 432 | 0.510 |
Why?
|
Female | 53 | 2024 | 391270 | 0.500 |
Why?
|
Anaphylaxis | 1 | 2022 | 755 | 0.500 |
Why?
|
Bacteremia | 1 | 2021 | 980 | 0.480 |
Why?
|
Fibrin Fibrinogen Degradation Products | 3 | 2021 | 418 | 0.470 |
Why?
|
Disclosure | 1 | 2020 | 738 | 0.460 |
Why?
|
Quality of Life | 10 | 2024 | 13308 | 0.460 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2022 | 3484 | 0.450 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 916 | 0.450 |
Why?
|
Middle Aged | 34 | 2024 | 220352 | 0.440 |
Why?
|
Perioperative Care | 2 | 2018 | 1037 | 0.440 |
Why?
|
Treatment Outcome | 20 | 2024 | 65017 | 0.440 |
Why?
|
Viral Vaccines | 1 | 2018 | 596 | 0.430 |
Why?
|
alpha-Thalassemia | 2 | 2024 | 52 | 0.430 |
Why?
|
Virus Diseases | 1 | 2018 | 720 | 0.410 |
Why?
|
Antibodies, Monoclonal | 2 | 2020 | 9185 | 0.410 |
Why?
|
Prognosis | 8 | 2023 | 29658 | 0.400 |
Why?
|
Recombinant Proteins | 1 | 2022 | 6538 | 0.400 |
Why?
|
Male | 41 | 2024 | 359744 | 0.390 |
Why?
|
Heart Diseases | 1 | 2024 | 2809 | 0.380 |
Why?
|
Clinical Trials as Topic | 3 | 2024 | 8056 | 0.380 |
Why?
|
Communication | 2 | 2022 | 3849 | 0.370 |
Why?
|
beta-Thalassemia | 2 | 2024 | 235 | 0.360 |
Why?
|
Antibodies, Neutralizing | 1 | 2020 | 1933 | 0.360 |
Why?
|
Bacterial Infections | 1 | 2018 | 1403 | 0.350 |
Why?
|
Pulmonary Embolism | 2 | 2020 | 2543 | 0.350 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2021 | 1459 | 0.340 |
Why?
|
Breast Neoplasms | 3 | 2022 | 21025 | 0.340 |
Why?
|
Cystic Fibrosis | 1 | 2019 | 1274 | 0.340 |
Why?
|
Practice Guidelines as Topic | 4 | 2021 | 7475 | 0.330 |
Why?
|
Retrospective Studies | 17 | 2023 | 80372 | 0.330 |
Why?
|
Double-Blind Method | 5 | 2024 | 12427 | 0.320 |
Why?
|
Heparin, Low-Molecular-Weight | 3 | 2020 | 345 | 0.320 |
Why?
|
Fibrinolytic Agents | 3 | 2023 | 2167 | 0.320 |
Why?
|
Aminopyridines | 2 | 2022 | 564 | 0.320 |
Why?
|
Erythrocyte Transfusion | 4 | 2024 | 566 | 0.310 |
Why?
|
Pierre Robin Syndrome | 1 | 2010 | 117 | 0.310 |
Why?
|
Aged | 21 | 2024 | 169152 | 0.310 |
Why?
|
Osteogenesis, Distraction | 1 | 2010 | 227 | 0.300 |
Why?
|
Peptide Fragments | 1 | 2020 | 5125 | 0.300 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6498 | 0.300 |
Why?
|
Prostate-Specific Antigen | 1 | 2017 | 2529 | 0.290 |
Why?
|
Recurrence | 5 | 2019 | 8482 | 0.280 |
Why?
|
Platelet Aggregation | 2 | 2021 | 805 | 0.280 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5889 | 0.260 |
Why?
|
Critical Illness | 5 | 2021 | 2709 | 0.260 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2024 | 5649 | 0.260 |
Why?
|
Mandible | 1 | 2010 | 750 | 0.260 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2023 | 3201 | 0.250 |
Why?
|
Lung Neoplasms | 2 | 2020 | 13262 | 0.240 |
Why?
|
Afibrinogenemia | 1 | 2024 | 18 | 0.240 |
Why?
|
Anemia, Hemolytic, Congenital | 1 | 2024 | 71 | 0.230 |
Why?
|
Atrial Fibrillation | 1 | 2023 | 5209 | 0.230 |
Why?
|
Iron | 2 | 2022 | 1786 | 0.230 |
Why?
|
Disease Susceptibility | 3 | 2019 | 1791 | 0.220 |
Why?
|
Complement Inactivating Agents | 1 | 2023 | 53 | 0.220 |
Why?
|
Erythropoiesis | 2 | 2024 | 682 | 0.220 |
Why?
|
Arteriovenous Malformations | 3 | 2023 | 397 | 0.220 |
Why?
|
Erythrocytes, Abnormal | 1 | 2023 | 121 | 0.210 |
Why?
|
Purpura, Thrombocytopenic | 1 | 2022 | 41 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.210 |
Why?
|
Administration, Oral | 3 | 2020 | 4035 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.200 |
Why?
|
Splanchnic Circulation | 1 | 2022 | 110 | 0.200 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2018 | 10827 | 0.200 |
Why?
|
Ferritins | 1 | 2024 | 597 | 0.200 |
Why?
|
Iron Chelating Agents | 1 | 2022 | 138 | 0.190 |
Why?
|
Child | 8 | 2022 | 79806 | 0.190 |
Why?
|
Drug Eruptions | 1 | 2024 | 335 | 0.190 |
Why?
|
Disease Management | 3 | 2021 | 2514 | 0.180 |
Why?
|
Stroke | 1 | 2023 | 9962 | 0.180 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2021 | 96 | 0.180 |
Why?
|
Bone Marrow Diseases | 1 | 2022 | 232 | 0.180 |
Why?
|
Bone Density | 2 | 2024 | 3534 | 0.180 |
Why?
|
Weight Gain | 1 | 2010 | 2347 | 0.170 |
Why?
|
Adenoviridae | 1 | 2024 | 1084 | 0.170 |
Why?
|
Prothrombin | 1 | 2020 | 191 | 0.170 |
Why?
|
Paternalism | 1 | 2019 | 47 | 0.170 |
Why?
|
Hemolysis | 1 | 2022 | 423 | 0.170 |
Why?
|
Young Adult | 9 | 2024 | 58741 | 0.170 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2021 | 146 | 0.170 |
Why?
|
Constipation | 1 | 2024 | 561 | 0.170 |
Why?
|
Menorrhagia | 1 | 2019 | 59 | 0.170 |
Why?
|
Portal Vein | 1 | 2022 | 429 | 0.170 |
Why?
|
Indazoles | 1 | 2021 | 302 | 0.170 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 1 | 2020 | 144 | 0.160 |
Why?
|
Ristocetin | 1 | 2018 | 26 | 0.160 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 642 | 0.160 |
Why?
|
Intensive Care Units | 3 | 2021 | 3736 | 0.160 |
Why?
|
Aged, 80 and over | 8 | 2022 | 58995 | 0.160 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 15789 | 0.160 |
Why?
|
Premedication | 1 | 2019 | 253 | 0.160 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 556 | 0.160 |
Why?
|
Hyperammonemia | 1 | 2020 | 77 | 0.160 |
Why?
|
Normal Distribution | 1 | 2019 | 273 | 0.160 |
Why?
|
Blood Coagulation Tests | 1 | 2019 | 270 | 0.160 |
Why?
|
Platelet Transfusion | 2 | 2018 | 294 | 0.160 |
Why?
|
Blood Loss, Surgical | 2 | 2019 | 656 | 0.160 |
Why?
|
Bilirubin | 1 | 2020 | 438 | 0.160 |
Why?
|
ABO Blood-Group System | 1 | 2020 | 369 | 0.150 |
Why?
|
Adenosine Diphosphate | 1 | 2018 | 429 | 0.150 |
Why?
|
Plasma Exchange | 1 | 2018 | 158 | 0.150 |
Why?
|
von Willebrand Factor | 1 | 2021 | 673 | 0.150 |
Why?
|
Reference Standards | 1 | 2021 | 1004 | 0.140 |
Why?
|
Patient Discharge | 1 | 2010 | 3476 | 0.140 |
Why?
|
Arachidonic Acid | 1 | 2018 | 433 | 0.140 |
Why?
|
Perioperative Period | 1 | 2018 | 264 | 0.140 |
Why?
|
Benzimidazoles | 1 | 2022 | 858 | 0.140 |
Why?
|
Length of Stay | 1 | 2010 | 6479 | 0.140 |
Why?
|
Risk Assessment | 5 | 2023 | 24123 | 0.140 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 4166 | 0.140 |
Why?
|
Risk Factors | 8 | 2023 | 74359 | 0.130 |
Why?
|
Genes, Dominant | 1 | 2019 | 863 | 0.130 |
Why?
|
Postpartum Hemorrhage | 1 | 2019 | 265 | 0.130 |
Why?
|
Severity of Illness Index | 3 | 2024 | 15840 | 0.130 |
Why?
|
Syndrome | 1 | 2022 | 3280 | 0.130 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1190 | 0.130 |
Why?
|
Salvage Therapy | 1 | 2022 | 1268 | 0.130 |
Why?
|
Rabbits | 1 | 2022 | 4773 | 0.130 |
Why?
|
Craniosynostoses | 1 | 2020 | 412 | 0.130 |
Why?
|
Advisory Committees | 1 | 2019 | 788 | 0.130 |
Why?
|
Heart Failure | 1 | 2019 | 11847 | 0.120 |
Why?
|
Critical Pathways | 1 | 2019 | 475 | 0.120 |
Why?
|
Epinephrine | 1 | 2018 | 791 | 0.120 |
Why?
|
Antithrombins | 1 | 2018 | 313 | 0.120 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2018 | 666 | 0.120 |
Why?
|
Fatigue | 1 | 2022 | 1544 | 0.120 |
Why?
|
Blood Transfusion | 1 | 2021 | 1328 | 0.120 |
Why?
|
Siblings | 1 | 2019 | 824 | 0.120 |
Why?
|
Pyridones | 1 | 2020 | 792 | 0.120 |
Why?
|
Risk | 2 | 2023 | 9631 | 0.120 |
Why?
|
Inpatients | 2 | 2023 | 2581 | 0.120 |
Why?
|
Living Donors | 1 | 2019 | 636 | 0.120 |
Why?
|
Amino Acid Substitution | 1 | 2018 | 1737 | 0.110 |
Why?
|
Drug Interactions | 1 | 2018 | 1428 | 0.110 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2234 | 0.110 |
Why?
|
Chronic Disease | 2 | 2018 | 9287 | 0.110 |
Why?
|
Combined Modality Therapy | 2 | 2023 | 8552 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2019 | 965 | 0.100 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2020 | 1613 | 0.100 |
Why?
|
ROC Curve | 1 | 2020 | 3568 | 0.100 |
Why?
|
Paralysis, Obstetric | 1 | 2012 | 12 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2864 | 0.100 |
Why?
|
Nitriles | 1 | 2017 | 956 | 0.100 |
Why?
|
Hospitalization | 3 | 2022 | 10790 | 0.100 |
Why?
|
Aortic Valve | 1 | 2022 | 1996 | 0.100 |
Why?
|
Liver Cirrhosis | 1 | 2022 | 1931 | 0.100 |
Why?
|
Benzamides | 1 | 2017 | 1369 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3157 | 0.100 |
Why?
|
Forecasting | 1 | 2021 | 2932 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2021 | 1588 | 0.100 |
Why?
|
Autoimmunity | 1 | 2019 | 1370 | 0.100 |
Why?
|
Sulfonamides | 1 | 2021 | 1977 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1941 | 0.090 |
Why?
|
Cost-Benefit Analysis | 1 | 2024 | 5508 | 0.090 |
Why?
|
Alleles | 2 | 2021 | 6898 | 0.090 |
Why?
|
Pyridines | 1 | 2022 | 2879 | 0.090 |
Why?
|
Brachial Plexus Neuropathies | 1 | 2012 | 122 | 0.090 |
Why?
|
Attention | 1 | 2021 | 2387 | 0.090 |
Why?
|
Neovascularization, Pathologic | 1 | 2021 | 2640 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4899 | 0.090 |
Why?
|
Collagen | 1 | 2018 | 2636 | 0.090 |
Why?
|
Animals | 5 | 2024 | 167963 | 0.090 |
Why?
|
Cohort Studies | 5 | 2024 | 41335 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10344 | 0.090 |
Why?
|
Veterans | 1 | 2023 | 2642 | 0.080 |
Why?
|
Aspartate Aminotransferases | 2 | 2022 | 416 | 0.080 |
Why?
|
Thrombolytic Therapy | 1 | 2018 | 2108 | 0.080 |
Why?
|
Prevalence | 3 | 2021 | 15687 | 0.080 |
Why?
|
Patient Compliance | 1 | 2020 | 2688 | 0.080 |
Why?
|
Adolescent | 4 | 2022 | 87810 | 0.080 |
Why?
|
Infant, Newborn | 3 | 2023 | 26181 | 0.080 |
Why?
|
Pyrimidines | 1 | 2021 | 3016 | 0.080 |
Why?
|
Alanine Transaminase | 2 | 2022 | 606 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3839 | 0.080 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14660 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2313 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3602 | 0.070 |
Why?
|
Prospective Studies | 2 | 2022 | 54303 | 0.070 |
Why?
|
Wounds and Injuries | 1 | 2019 | 2477 | 0.070 |
Why?
|
Survival Rate | 1 | 2021 | 12808 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 8950 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5643 | 0.070 |
Why?
|
Incidence | 1 | 2024 | 21392 | 0.070 |
Why?
|
United States | 5 | 2022 | 72461 | 0.070 |
Why?
|
Genetic Testing | 1 | 2019 | 3531 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3865 | 0.060 |
Why?
|
Pregnancy | 3 | 2024 | 29749 | 0.060 |
Why?
|
Mutation | 5 | 2023 | 29932 | 0.060 |
Why?
|
Terminology as Topic | 1 | 2012 | 1535 | 0.060 |
Why?
|
Rats | 1 | 2021 | 23711 | 0.060 |
Why?
|
Enteral Nutrition | 1 | 2010 | 785 | 0.060 |
Why?
|
Pandemics | 2 | 2022 | 8624 | 0.060 |
Why?
|
Logistic Models | 1 | 2018 | 13314 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7408 | 0.050 |
Why?
|
Activin Receptors, Type II | 1 | 2023 | 124 | 0.050 |
Why?
|
Cell Shape | 1 | 2023 | 372 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25942 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15289 | 0.050 |
Why?
|
Blood Coagulation Factors | 1 | 2024 | 365 | 0.050 |
Why?
|
Alanine | 1 | 2024 | 606 | 0.050 |
Why?
|
Infant | 2 | 2020 | 36060 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11712 | 0.050 |
Why?
|
Hemostasis | 1 | 2023 | 468 | 0.050 |
Why?
|
Fibrinogen | 1 | 2024 | 886 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39261 | 0.040 |
Why?
|
Splenectomy | 1 | 2022 | 391 | 0.040 |
Why?
|
Cranial Sutures | 1 | 2020 | 92 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17790 | 0.040 |
Why?
|
Mycophenolic Acid | 1 | 2021 | 343 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 13981 | 0.040 |
Why?
|
Ammonia | 1 | 2020 | 236 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2021 | 859 | 0.040 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2023 | 841 | 0.040 |
Why?
|
Hemostasis, Surgical | 1 | 2018 | 129 | 0.040 |
Why?
|
Time Factors | 1 | 2019 | 40165 | 0.040 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2024 | 1355 | 0.040 |
Why?
|
Sutures | 1 | 2020 | 293 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1724 | 0.040 |
Why?
|
Child, Preschool | 1 | 2020 | 42063 | 0.040 |
Why?
|
Alkaline Phosphatase | 1 | 2020 | 865 | 0.030 |
Why?
|
Genotype | 2 | 2021 | 12960 | 0.030 |
Why?
|
Heparin | 1 | 2023 | 1652 | 0.030 |
Why?
|
Genetic Diseases, Inborn | 1 | 2020 | 601 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15697 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2326 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2421 | 0.030 |
Why?
|
Triglycerides | 1 | 2022 | 2476 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1091 | 0.030 |
Why?
|
Vitamins | 1 | 2022 | 1634 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2803 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2021 | 1869 | 0.030 |
Why?
|
Warfarin | 1 | 2020 | 1518 | 0.020 |
Why?
|
Cause of Death | 1 | 2021 | 3725 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3061 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3928 | 0.020 |
Why?
|
Mortality | 1 | 2021 | 2916 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4541 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2020 | 2056 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2018 | 2717 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9280 | 0.020 |
Why?
|
Echocardiography | 1 | 2020 | 4981 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2021 | 5425 | 0.020 |
Why?
|
Canada | 1 | 2012 | 2128 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3696 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10551 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6551 | 0.020 |
Why?
|
International Cooperation | 1 | 2012 | 1433 | 0.020 |
Why?
|
Neurosurgery | 1 | 2012 | 670 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20080 | 0.020 |
Why?
|
Europe | 1 | 2012 | 3441 | 0.020 |
Why?
|
Liver | 1 | 2020 | 7509 | 0.010 |
Why?
|
Consensus | 1 | 2012 | 3113 | 0.010 |
Why?
|
Signal Transduction | 1 | 2023 | 23376 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16546 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20509 | 0.010 |
Why?
|